Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Celcuity Inc. | VIZIMPRO (dacomitinib) and XALKORI (crizotinib) - (FACT-3) | HER2-negative breast cancer | Phase 2 | Trial Discontinued | Oral | Oncology |
| Celcuity Inc. | NERLYNX (neratinib) and FASLODEX (fulvestrant) - (FACT-4) | HR-positive, HER2-negative breast cancer | Phase 2 | Trial Planned | NERLYNX oral FASLODEX intramuscular | Oncology |
| Celcuity Inc. | NERLYNX (neratinib) and Xeloda (capecitabine) | HER2-negative breast cancer | Phase 2 | Trial Planned | Oral | Oncology |
| Celcuity Inc. | AC-THP CELsignia - (FACT-1) | HER2-Negative Breast Cancer | Phase 2 | Ongoing | Intravenous | Oncology |
| Celcuity Inc. | NERLYNX (Neratinib) CELsignia - (FACT-2) | Triple Negative Breast Cancer | Phase 2 | Trial Discontinued | Oral | Oncology |
| Celcuity Inc. | NERLYNX (Neratinib) CELsignia - (FACT-2) | Triple Negative Breast Cancer | Phase 2 | Trial Discontinued | Oral | Oncology |
| Celldex Therapeutics Inc. | CDX-3379 | Recurrent/metastatic head and neck squamous cell cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Celldex Therapeutics Inc. | Glembatumumab vedotin | Metastatic triple negative breast cancers that overexpress gpNMB | Phase 2b | Trial Discontinued | Intravenous | Oncology |
